New US Hemp Rules Take Effect December 11, Shifting Demand for South American Exporters

Section 781 changes the federal hemp standard from delta-9 THC alone to total THC. Total THC includes THCA, and finished hemp-derived cannabinoid products may contain no more than 0.4 milligrams of total THC per container. Most provisions take full effect on December 11.

That favors non-intoxicating products made with THC-free ingredients. CBD isolate and broad-spectrum distillate, with THC removed, have a clearer path than raw flower or full-spectrum oil. Colorado-based Joy Organics provides an example with USDA-certified organic CBD gummies and third-party tests showing non-detectable THC.

The change concentrates demand on tested ingredients and compliant finished goods. US brands are expected to require supplier lab reports and batch records. Raw flower faces the greatest risk because THCA can push total THC above the limit, although Congress could still change the framework after December 11.

Total THC is the new measurement for hemp compliance. Laboratories calculate it as delta-9 THC plus 0.877 times the THCA content. The change matters because the old federal test looked only at delta-9 THC, while the new standard also counts the THC that can be represented by THCA.

For example, raw flower may contain little enough delta-9 THC to pass the old rule. Its THCA content can nevertheless raise the calculated total above the permitted level. That makes flower especially exposed, even when its delta-9 result appears compliant.

The same calculation affects finished goods, which must stay below 0.4 milligrams of total THC per container. Products using THC-free ingredients avoid much of this problem. CBD isolate and broad-spectrum distillate are therefore better positioned than whole flower and full-spectrum oil.

The scale of the risk is broad. The US Hemp Roundtable estimates that the new federal definition could eliminate about 95% of existing hemp-derived cannabinoid products. Stakeholders also expect the per-container limit to rule out most full-spectrum CBD products.

The key limit is 0.4 milligrams of total THC in each finished hemp-derived cannabinoid product container. Compliance now uses total THC, not delta-9 THC alone, so THCA contributes to the calculation. A product can therefore fail even if its delta-9 level once passed the older standard.

This puts much of the current market under pressure, especially flower and full-spectrum products. The likely surviving category is narrower: CBD and other non-intoxicating cannabinoids in finished goods that remain below the cap. THC-free inputs offer suppliers and brands a more predictable route.

South American exporters that depend on raw hemp flower face a much harder US market. The new rule counts THCA as well as delta-9 THC, so flower is more exposed than processed, THC-free ingredients. Exporters may need to redirect sales, change products, or await further action from Congress.

Uruguay shows the trade’s existing scale. The country recorded its first hemp export in 2020 and sent 10 tonnes of CBD flower to the United States in 2023, its largest shipment of that kind. That type of shipment now faces the new calculation at the laboratory stage.

Laboratories calculate total THC as delta-9 THC plus 0.877 times THCA. Flower that met the old test can fail the new one. The article notes that raw flower depends on what Congress does next, while THC-free inputs fit the rules as written more securely.

As flower and full-spectrum products face tighter limits, demand is likely to move toward non-intoxicating cannabinoids in finished goods that remain under the cap. The strongest position belongs to ingredients with no detectable THC, because they reduce the risk of exceeding the 0.4-milligram total-THC limit per container.

The article identifies CBD isolate and broad-spectrum distillate as the main alternatives. Broad-spectrum distillate has had THC removed, while CBD isolate is a THC-free input. These ingredients can be used in products such as gummies, softgels, and tinctures, provided the finished goods comply.

Joy Organics illustrates the model. It sells USDA-certified organic CBD gummies in 10, 25, and 50 milligram strengths and uses third-party testing to confirm non-detectable THC. Its batch results are posted online, showing how product formulation and documentation work together.

Testing and records matter because US brands already publish lab reports for gummies, softgels, and tinctures. They are expected to demand comparable evidence from suppliers. Batch-level results can show that ingredients contain non-detectable THC or remain within the total-THC limit.

Organic certification adds another requirement. Joy Organics uses USDA organic certification, and US organic labeling depends on certified organic ingredients. That means documentation must travel back through the supply chain to the grower and extractor. Exporters with organic certification may therefore gain an advantage.

The need applies across a region with different regulatory starting points. Colombia has permitted hemp production for medical and scientific purposes since 2016. Argentina created a medical cannabis and industrial hemp framework in 2022. Brazil now allows authorised companies to grow hemp for medicinal and research purposes, including export-oriented cultivation.

In general usage, hemp refers to cannabis cultivated under legal limits for THC. CBD is a cannabinoid associated with non-intoxicating effects. THC is the cannabinoid responsible for intoxication. THCA is an acidic form of THC found in raw plant material; when counted for compliance, it contributes to total THC under the article’s formula.

A hemp product can contain CBD without producing an intoxicating effect when its THC content is absent or very low. CBD isolate contains CBD without THC, while broad-spectrum distillate is processed to remove THC. The article’s example is Joy Organics’ gummies, whose third-party testing confirms non-detectable THC.

This distinction matters because the new rules count both delta-9 THC and THCA. The article does not provide chemical definitions for these compounds; the basic descriptions above use established scientific knowledge. Under the new standard, CBD content alone does not determine compliance.